| Use of myostatin inhibitor and combination therapy |
2023-9-01 |
2023-11-14 |
|
| Isoform-specific, context-permissive tgfb1 inhibitors and use thereof |
2023-8-01 |
2024-1-18 |
|
| Compositions and methods for growth factor modulation |
2023-7-20 |
2023-10-24 |
|
| Anti-pro/latent-Myostatin antibodies and uses thereof |
2023-6-21 |
2023-7-13 |
|
| TGFβ1-BINDING IMMUNOGLOBULINS AND USE THEREOF |
2023-6-19 |
2023-8-03 |
|
| Use of myostatin inhibitor for treating spinal muscular atrophy |
2023-5-03 |
2023-11-09 |
|
| Anti-pro/latent myostatin antibodies and methods of use thereof |
2022-11-21 |
2023-2-07 |
|
| Methods for treating metabolic diseases by inhibiting myostatin activation |
2022-11-08 |
2022-12-15 |
|
| Anti-pro/latent-myostatin antibodies and uses thereof |
2022-8-19 |
2022-11-01 |
|
| LTBP COMPLEX-SPECIFIC INHIBITORS OF TGFβ1 AND USES THEREOF |
2022-7-14 |
2023-12-28 |
|
| TGFB antibodies, methods and uses |
2022-7-05 |
2022-10-12 |
|
| Therapies for weight management and related metabolic conditions |
2022-6-23 |
2023-5-01 |
|
| Tgf-beta inhibitors and therapeutic use thereof |
2022-6-03 |
2022-12-08 |
|
| LTBP COMPLEX-SPECIFIC INHIBITORS OF TGFb AND USES THEREOF |
2022-5-17 |
2022-11-17 |
|
| Tgf-beta inhibitors and use thereof |
2022-3-25 |
2022-9-29 |
|
| Tgf-beta inhibitors and use thereof |
2022-3-25 |
2024-2-07 |
|
| TGFB1 ISOFORM-SELECTIVE INHIBITORS AND THEIR USE |
2022-1-28 |
2023-6-09 |
|
| Use of anti-pro/latent myostatin antibody for treating spinal muscular atrophy |
2021-10-25 |
2023-6-01 |
|
| Selective rgmc inhibitors and their use |
2021-4-22 |
2021-9-24 |
|
| Isoform-selective, high-affinity tgfβ1 inhibitors and uses thereof |
2021-1-18 |
2021-1-29 |
|
| Tgf-beta inhibitors and use thereof |
2021-1-11 |
2021-7-15 |
|
| TGFb INHIBITORS AND THEIR USE |
2021-1-11 |
2022-4-06 |
|
| Tgfbeta inhibitors and use thereof |
2021-1-11 |
2022-11-16 |
|
| Compositions and methods for modulating cell signaling |
2019-11-14 |
2019-12-05 |
|
| TGFb1 INHIBITORS AND USE OF THEM |
2019-7-11 |
2021-2-24 |
|
| ISOFORM SELECTIVE HIGH AFFINITY TGFb1 INHIBITORS AND THEIR USES |
2019-7-11 |
2021-2-24 |
|
| TGFβ1 INHIBITORS AND USE THEREOF |
2019-7-11 |
2020-2-13 |
|
| SPECIFIC INHIBITORS OF THE TGF-BETA 1 LTBP COMPLEX AND THEIR USES |
2018-7-27 |
2021-5-19 |
|
| Lrrc33 inhibitors and use thereof |
2018-5-09 |
2024-2-05 |
|
| Methods for treating metabolic diseases by inhibiting myostatin activation |
2018-1-05 |
2023-5-31 |
|
| Use of myostatin inhibitors and combination therapies |
2017-6-13 |
2022-7-01 |
|
| Use of myostatin inhibitors and combination therapies |
2017-6-13 |
2022-7-01 |
|
| Use of myostatin inhibitors and combination therapies |
2017-6-13 |
2022-7-01 |
|
| Primed growth factors and uses thereof |
2016-10-26 |
2017-5-04 |
|
| Gdf11 binding proteins and uses thereof |
2016-7-22 |
2018-5-30 |
|
| Transforming growth factor-related immunoassays |
2015-11-06 |
2016-7-21 |
|
| Compositions and methods for growth factor modulation |
2015-5-06 |
2016-3-10 |
|